Research graph
References from Initiation of inhaled antibiotic therapy in chronic airway diseases: the REPAIR registry. Local targets link to admitted publications; unresolved targets remain external evidence.
The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis
10.1016/j.chest.2024.01.045 · 2024 · External reference
Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study
10.1016/j.arbres.2021.03.009 · 2022 · External reference
10.1128/cmr.00101-15
10.1128/cmr.00101-15 · External reference
Advances in inhaled antibiotics for management of respiratory tract infections
10.1097/mcp.0000000000000952 · 2023 · External reference
Spanish guidelines on treatment of bronchiectasis in adults
10.1016/j.arbr.2017.07.014 · 2018 · External reference
10.1136/bmjresp-2018-000348
10.1136/bmjresp-2018-000348 · External reference
10.1183/13993003.01126-2025
10.1183/13993003.01126-2025 · External reference
Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease
10.1016/j.arbres.2020.04.023 · 2020 · External reference
Update 2025 of the Spanish COPD GUIDELINES (GesEPOC): pharmacological treatment of stable COPD
10.1016/j.arbres.2025.10.008 · 2025 · External reference
Bronchiectasis in COPD patients: more than a comorbidity?
10.2147/copd.s132961 · 2017 · External reference
The association between bronchiectasis and chronic obstructive pulmonary disease: data from the European bronchiectasis registry (EMBARC)
10.1164/rccm.202309-1614oc · 2024 · External reference
10.1016/j.jaci.2024.01.027
10.1016/j.jaci.2024.01.027 · External reference
Phenotype analysis of chronic bronchial infection patients on inhaled antibiotic therapy: a multicentre retrospective cohort study in Spain (INBREATHING study)
10.1016/j.arbres.2025.04.008 · 2025 · External reference
Unraveling the enigma: Spain takes a pioneering step with REPAIR in the world of inhaled antibiotics
10.1016/j.arbres.2024.01.007 · 2024 · External reference
10.1001/jama.2013.281053
10.1001/jama.2013.281053 · External reference
Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults
10.1016/j.arbr.2017.07.013 · 2018 · External reference
RIBRON: the Spanish Online bronchiectasis registry. characterization of the first 1912 patients
10.1016/j.arbr.2020.11.010 · 2021 · External reference
Inhaled dry powder antibiotics in patients with non-cystic fibrosis bronchiectasis: efficacy and safety in a real-life study
10.3390/jcm9072317 · 2020 · External reference
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
10.1016/s2213-2600(23)00093-0 · 2023 · External reference
Use of long-term inhaled antibiotics and macrolides: insights from the four global bronchiectasis registries
10.21037/jtd-2025-1370 · 2025 · External reference
10.1513/annalsats.201506-333oc
10.1513/annalsats.201506-333oc · External reference
Current challenges in chronic bronchial infection in patients with chronic obstructive pulmonary disease
10.3390/jcm9061639 · 2020 · External reference
Impact of Pseudomonas aeruginosa infection on patients with chronic inflammatory airway diseases
10.3390/jcm9123800 · 2020 · External reference
Chronic bronchial infection is associated with more rapid lung function decline in chronic obstructive pulmonary disease
10.1513/annalsats.202108-974oc · 2022 · External reference
POINT: is chronic bacterial infection clinically relevant in COPD? Yes
10.1016/j.chest.2022.07.010 · 2022 · External reference
[Experience with nebulised colistin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa]
2019 · External reference
Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis
10.1177/1479973119872513 · 2019 · External reference
10.2147/copd.s209513
10.2147/copd.s209513 · External reference
Results of tobramycin inhalation therapy in patients with noncystic fibrosis bronchiectasis with Pseudomonas aeruginosa colonization: real life management
10.1089/jamp.2020.1606 · 2021 · External reference
The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis
10.1016/s2213-2600(19)30185-7 · 2019 · External reference
Safety and efficacy of devices delivering inhaled antibiotics among adults with non-cystic fibrosis bronchiectasis: a systematic review and a network meta-analysis
10.3390/antibiotics11020275 · 2022 · External reference
Efficacy and safety of dry powder antibiotics: a narrative review
10.3390/jcm12103577 · 2023 · External reference
Clinical characteristics and outcomes of the phenotypes of COPD-Bronchiectasis Association
10.1016/j.arbres.2024.04.003 · 2024 · External reference
Phenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine
10.21037/jtd-2024-1945 · 2025 · External reference
The phenotypes of asthma–bronchiectasis overlap: clinical characteristics and outcomes
10.4168/aair.2025.17.2.196 · 2025 · External reference
C-reactive protein concentration in steady-state bronchiectasis: prognostic value of future severe exacerbations. Data from the Spanish Registry of Bronchiectasis (RIBRON)
10.1016/j.arbr.2019.12.022 · 2021 · External reference
10.1183/16000617.0234-2023
10.1183/16000617.0234-2023 · External reference
10.1186/s12931-025-03356-w
10.1186/s12931-025-03356-w · External reference
Type 2 biomarkers and their clinical implications in bronchiectasis: a prospective cohort study
10.1007/s00408-024-00707-0 · 2024 · External reference
